Hereditary breast and/or ovarian cancer syndromes are inherited disorders in which there is an increased risk of developing breast and/or ovarian cancer in the lifetime, usually at a younger age compared to the general population. Cancer prevention in these syndromes includes prophylactic surgeries, personalized surveillance programs and chemopreventive strategies. Chemoprevention exploits the use of certain drugs or other substances to help lower the risk of developing cancer. In this context, tamoxifen was the first agent considered for breast cancer prevention, followed by raloxifene and the third-generation aromatase inhibitors. On the other hand, the first and most widespread type of chemoprevention for ovarian cancer was combined hormonal contraceptive use. Although several strategies have been studied and showed promising results, only a few of these are currently applied in daily clinical practice. Side effects along with several psychological variables such as cancer perceived risk, worries and related distress, strongly influence women’s decision on chemoprevention. The present review explores and summarizes the available evidence on breast and ovarian cancer chemoprevention approaches.
PetrucelliNDalyMBPalT, et al. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: AdamMP, et al. (eds) GeneReviews. Seattle, WA: University of Washington, 1993, pp.
SessaC, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol2023; 34: 33–47.
6.
LiX, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clin Cancer Res Off J Am Assoc Cancer Res2016; 22: 3971–3981.
7.
HonoldFCamusM.Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women’s BRCA carriers. Medwave2018; 18: e7161.
8.
KauffND, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol Off J Am Soc Clin Oncol2008; 26: 1331–1337.
9.
RebbeckTRKauffNDDomchekSM.Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009; 101: 80–87.
10.
FinchAPM, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol Off J Am Soc Clin Oncol2014; 32: 1547–1553.
11.
KathawalaRJKudelkaARigasB.The chemoprevention of ovarian cancer: the need and the options. Curr Pharmacol Rep2018; 4: 250–260.
12.
Landis-PiwowarKRIyerN.R.Cancer chemoprevention: current state of the art. Cancer Growth Metastasis2014; 7: 19–25.
13.
NelsonHDFuRZakherB, et al. Medication use for the risk reduction of primary breast cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA2019; 322: 868.
14.
NelsonHDSmithMEGriffinJC, et al. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine158: 604–14.
15.
FisherB, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI J Natl Cancer Inst1998; 90: 1371–1388.
16.
JordanVC.Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov2003; 2: 205–213.
17.
KommBSMirkinS.An overview of current and emerging SERMs. J Steroid Biochem Mol Biol2014; 143: 207–222.
PaterniIGranchiCKatzenellenbogenJA, et al. Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential. Steroids2014; 90: 13–29.
20.
DalalH, et al. Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors. Sci Rep2022; 12: 4696.
21.
ZhouYLiuX.The role of estrogen receptor beta in breast cancer. Biomark Res2020; 8: 39.
22.
ShenK, et al. Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression. Pharmacol Ther2023; 242: 108350.
23.
RajanA, et al. Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis. Biochim Biophys Acta BBA - Rev Cancer2021; 1875: 188482.
24.
ShanleEKXuW.Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev2010; 62: 1265–1276.
25.
FabianCJKimlerBF.Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol2005; 23: 1644–1655.
26.
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet1998; 351: 1451–1467.
27.
TyrerJDuffySWCuzickJ.A breast cancer prediction model incorporating familial and personal risk factors. Stat Med2004; 23: 1111–1130.
28.
EMBRACE Group, et al. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res2014; 16: 3419.
29.
LiWXiaoCVonderhaarBK, et al. A role of estrogen/ERα signaling in BRCA1-associated tissue-specific tumor formation. Oncogene2007; 26: 7204–7212.
30.
NarodSA, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet2000; 356: 1876–1881.
31.
KingM-C.Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA2001; 286: 2251.
32.
XuL, et al. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis. Breast Cancer2015; 22: 327–334.
33.
PowlesTJ, et al. Prevention of breast cancer with tamoxifen—an update on the royal Marsden Hospital pilot programmeEur J Cancer Clin Oncol1990; 26: 680–684.
34.
PowlesT, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet1998; 352: 98–101.
35.
PowlesTJAshleySTidyA, et al. Twenty-year follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial. JNCI J Natl Cancer Inst2007; 99: 283–290.
36.
CuzickJ, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I Trial. JNCI J Natl Cancer Inst2007; 99: 272–282.
37.
CuzickJ, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol2015; 16: 67–75.
38.
VeronesiU, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. JNCI J Natl Cancer Inst2007; 99: 727–737.
39.
DecensiA, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. JNCI J Natl Cancer Inst2003; 95: 779–790.
40.
DecensiA, et al. Biologic activity of tamoxifen at low doses in healthy women. JNCI J Natl Cancer Inst1998; 90: 1461–1467.
41.
DecensiA, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol1999; 17: 2633–2633.
42.
CohenI, et al. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer patients. Breast Cancer Res Treat1999; 53: 255–262.
43.
DeCensiA, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol2019; 37: 1629–1637.
44.
LazzeroniM, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 Study. J Clin Oncol2023; 41: 3116–3121.
45.
VisvanathanK, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO Clinical Practice Guideline update. J Clin Oncol2019; 37: 3152–3165.
46.
DeCensiA, et al. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol2013; 24: 2753–2760.
47.
Fuchs-YoungR, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci1995; 761: 355–360.
48.
CummingsSR, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA1999; 281: 2189.
49.
CauleyJA, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE Trial. Breast Cancer Res Treat2001; 65: 125–134.
50.
MartinoS, et al. Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. JNCI J Natl Cancer Inst2004; 96: 1751–1761.
51.
Barrett-ConnorE, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006; 355: 125–137.
52.
GradyD, et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. JNCI J Natl Cancer Inst2008; 100: 854–861.
53.
WickerhamDL, et al. Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. J Clin Oncol2015; 33: 1500–1500.
54.
VogelVGCostantinoJPWickerhamDL, et al. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin. Breast Cancer2002; 3: 153–159.
55.
VogelVG.The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther2009; 9: 51–60.
56.
WickerhamDL, et al. The use of tamoxifen and raloxifene for the prevention of breast cancer. In: SennH-JKappUOttoF. (eds) Cancer Prevention II. Berlin: Springer Berlin Heidelberg, pp. 113–119.
57.
HowellA, et al. RAZOR: A Phase II open randomized trial of screening plus goserelin and raloxifene versus screening alone in premenopausal women at increased risk of breast cancer. Cancer Epidemiol Biomarkers Prev2018; 27: 58–66.
58.
PujolP, et al. Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. Fam Cancer2012; 11: 77–84.
59.
PujolP, et al. Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial. J Clin Oncol2020; 38: 1534–1534.
60.
Nemati ShafaeeM, et al. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Res Treat2022; 196: 143–152.
61.
CuzickJ, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet2014; 383: 1041–1048.
62.
CuzickJ, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet2020; 395: 117–122.
63.
SestakI, et al. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncol2014; 15: 1460–1468.
64.
GossPE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med2011; 364: 2381–2391.
65.
Gatti-MaysME, et al. Exemestane use in postmenopausal women at high risk for invasive breast cancer: evaluating biomarkers of efficacy and safety. Cancer Prev Res (Phila Pa)2016; 9: 225–233.
66.
ChlebowskiRT, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol2010; 28: 3582–3590.
67.
RennertGPinchevMRennertHS.Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol2010; 28: 3577–3581.
68.
HueTF, et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med2014; 174: 1550.
69.
LeeHJ, et al. Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells. Development2013; 140; 1397–1401.
70.
KimJOktayK.Baseline E2 levels are higher in BRCA2 mutation carriers: a potential target for prevention?Cancer Causes Cont2013; 24: 421–426.
71.
SingerCF.Nonsurgical prevention strategies in BRCA1 and BRCA2 mutation carriers. Breast Care2021; 16: 144–148.
72.
SiglV, et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res2016; 26: 761–774.
73.
NolanE, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med2016; 22: 933–939.
74.
FranciosiM, et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS ONE2013; 8: e71583.
75.
DeCensiA, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila Pa)2010; 3: 1451–1461.
76.
NotoHGotoATsujimotoT, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS ONE2012; 7: e33411.
77.
ChlebowskiRT, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol2012; 30: 2844–2852.
78.
CairatM, et al. Antiplatelet drug use and breast cancer risk in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev2021; 30: 643–652.
79.
LuLShiLZengJ, et al. Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants. Oncotarget2017; 8: 40389–40401.
80.
VeronesiU, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. JNCI J Natl Cancer Inst1999; 91: 1847–1856.
81.
VeronesiU, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol2006; 17: 1065–1071.
82.
SimeoneA-M, et al. N -(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1 -mutated breast cancer cells. Carcinogenesis2005; 26: 1000–1007.
83.
PritchardKI.Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?Ann Oncol2006; 17: 1035–1036.
84.
AristarcoV, et al. Fenretinide in young women at genetic or familial risk of breast cancer: a placebo-controlled biomarker trial. Cancer Prev Res (Phila Pa)2024; 17: 255–263.
85.
ThompsonPA, et al. Sulindac, a nonselective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors. Clin Cancer Res2021; 27: 5660–5668.
86.
MartinezJA, et al. Sulindac improves stiffness and quality of life in women taking aromatase inhibitors for breast cancer. Breast Cancer Res Treat2022; 192: 113–122.
87.
TossA, et al. The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. Oncotarget2017; 8: 9144–9154.
88.
GrandiG, et al. Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history. Clin Breast Cancer2018; 18: e15–e24.
89.
LazzeroniM, et al. Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo. BMC Cancer2012; 12: 575.
90.
YerushalmiR, et al. 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial. Carcinogenesis2020; 41: 1395–1401.
91.
Collaborative Group on Epidemiological Studies of Ovarian Cancer, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet2008; 371: 303–314.
92.
HavrileskyLJ, et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol2013; 122: 139–147.
93.
Sánchez-BorregoRSánchez-PrietoM.What are the mechanisms of action of the different contraceptive methods to reduce the risk of ovarian cancer?Eur J Contracept Reprod Health Care Off J Eur Soc Contracept2021; 26: 79–84.
94.
AvramenkoASFlanaganJM.An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use. Clin Epigenetics2023; 15: 165.
95.
IversenL, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ2018; k3609: 10.1136/bmj.k3609.
96.
ParkJHuangDChangYJ, et al. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies. Carcinogenesis2022; 43: 231–242.
97.
IodiceS, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer Oxf Engl 19902021; 46: 2275–2284.
98.
CibulaDZikanMDusekL, et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther2011; 11: 1197–1207.
99.
MoormanPG, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol2013; 31: 4188–4198.
100.
Van BommelMHD, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update2023; 29: 197–217.
101.
SchrijverLH, et al. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. Am J Obstet Gynecol2021; 225: 51.e1-51.e17.
102.
MartínezFAvecillaA.Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care2007; 12: 97–106.
103.
StegemanBH, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ2013; 347: f5298.
104.
GadducciACosioSFruzzettiF.Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. Anticancer Res2020; 40: 5995–6002.
105.
BosettiCBraviFNegriE, et al. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis. Hum Reprod Update2009; 15: 489–498.
106.
CibulaD, et al. Hormonal contraception and risk of cancer. Hum Reprod Update2010; 16: 631–650.
107.
FitzpatrickDPirieKReevesG, et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis. PLOS Med2023; 20: e1004188.
108.
LiL, et al. Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis. Mol Clin Oncol2017; 7: 76–80.
109.
Asselin-LabatM-L, et al. Control of mammary stem cell function by steroid hormone signalling. Nature2010; 465: 798–802.
RajaramRD, et al. Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk. EMBO J2015; 34: 641–652.
112.
GrandiGSammariniMChiara Del SavioM, et al. Combined hormonal contraceptives in BRCA gene mutation carriers: why not?Eur J Contracept Reprod Health Care2019; 24: 417–419.
113.
GarciaC, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol2014; 132: 428–433.
114.
LoizziV, et al. Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women. Hormones2024; 23(2): 277-286. doi:10.1007/s42000-023-00519-6.
115.
GrandiG, et al. BRCA mutation carriers’ perception about benefits and risks associated with combined hormonal contraceptives use. Eur J Contracept Reprod Health Care2022; 27: 439–444.
116.
FlemingJSBeaugiéCRHavivI, et al. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses. Mol Cell Endocrinol2006; 247: 4–21.
117.
HurwitzLM, et al. Modification of the association between frequent aspirin use and ovarian cancer risk: a meta-analysis using individual-level data from two ovarian cancer consortia. J Clin Oncol2022; 40: 4207–4217.
118.
ZhangDBaiBXiY, et al. Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecol Oncol2016; 142: 368–377.
119.
TrabertB, et al. Analgesic use and ovarian cancer risk: an analysis in the ovarian cancer cohort consortium. JNCI J Natl Cancer Inst2019; 111: 137–145.
120.
TrabertB, et al. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the ovarian cancer association consortium. JNCI J Natl Cancer Inst2014; 106: djt431–djt431.
121.
AmmundsenHB, et al. Use of analgesic drugs and risk of ovarian cancer: results from a Danish case–control study. Acta Obstet Gynecol Scand2012; 91: 1094–1102.
122.
BaandrupL, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta Obstet Gynecol Scand2013; 92: 245–255.
123.
SetiawanVW, et al. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev2012; 21: 1441–1449.
124.
ChiyodaT, et al. Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: a window of opportunity for ovarian cancer chemoprevention. Cancer Prev Res (Phila Pa)2017; 10: 255–266.
125.
UrayIPDmitrovskyEBrownPH.Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol2016; 43: 49–64.
126.
SupinoR, et al. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer1996; 65: 491–497.
127.
De PaloG, et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol2002; 86: 24–27.
128.
WoźniakMKrajewskiRMakuchS, et al. Phytochemicals in gynecological cancer prevention. Int J Mol Sci2021; 22: 1219.
129.
FlanaganMR, et al. Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann Surg Oncol2019; 26: 2127–2135.
130.
PadamseeTJWillsCEYeeLD, et al. Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res2017; 19: 34.
131.
Julian-ReynierCM, et al. Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: Differences among English, French, and Canadian women. Cancer2001; 92: 959–968.
132.
MeiserB, et al. Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract2017; 15: 14.
133.
ForrestLEForbes ShepherdRYoungM, et al. Finding the five-year window: A qualitative study examining young women’s decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk. Psychooncology2021; 30: 159–166.
134.
SmithSG, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol2016; 27: 575–590.
135.
RazzaboniE, et al. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). Breast J2013; 19: 10–21.
136.
PadamseeTJHilsMMuravevaA.Understanding low chemoprevention uptake by women at high risk of breast cancer: findings from a qualitative inductive study of women’s risk-reduction experiences. BMC Womens Health2021; 21: 157.
137.
HoergerMSchererLDFagerlinA.Affective forecasting and medication decision making in breast-cancer prevention. Health Psychol2016; 35: 594–603.
138.
CrewKD.Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. Am Soc Clin Oncol Educ Book2015; e50–e58.
139.
WernliKJ, et al. Effect of personalized breast cancer risk tool on chemoprevention and breast imaging: ENGAGED-2 Trial. JNCI Cancer Spectr2021; 5: pkaa114.
140.
CortesiLRugoHSJackischC.An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol2021; 16: 255–282.
141.
LaFargueCJDal MolinGZSoodAK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol2019; 20: e15–e28.
142.
CuzickJ, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol2015; 16: 67–75.
